Outcomes of Metabolic and Bariatric Surgery in Patients with Inflammatory Bowel Disease: A Long-Term Retrospective...

Background: Metabolic and bariatric surgery (MBS) is a well-established treatment for severe obesity, yet its effects in patients with inflammatory bowel disease (IBD) are not well understood. MBS in this population presents unique challenges, including the potential for exacerbating inflammatory disease activity and causing complications such as malnutrition and medication malabsorption. This study aims to assess the long-term outcomes of MBS in IBD patients, focusing on both metabolic outcomes and its impact on the course of IBD. Methods: A retrospective analysis was conducted on 20 patients with IBD who underwent MBS at a tertiary center between 2005 and 2019. Data on baseline characteristics, surgical procedures, complications, weight loss, resolution of obesity-related diseases, and IBD-related outcomes were collected. Results: The cohort, primarily female (65%), had a mean preoperative body mass index (BMI) of 40.8 kg/m². The MBS procedures performed were sleeve gastrectomy (n = 9), Roux-en-Y gastric bypass (n = 6), one-anastomosis gastric bypass (n = 2), and Laparoscopic Adjustable Gastric Banding (n = 3). No major 30-day complications were recorded. At a median follow-up of 91 months, the mean BMI decreased by 9.5 kg/m², with satisfactory outcomes in terms of resolution of obesity-related diseases. IBD activity scores increased postoperatively, particularly in Crohn's disease (CD) patients, although these changes were not statistically significant. In addition, 30% of patients were hospitalized due to IBD exacerbation, and 15% required surgical intervention for IBD. Conclusions: MBS is an effective treatment for severe obesity and its related diseases in IBD patients. While encountering no major complications or mortality, some long-term complications were observed, with a possible increase in IBD activity, particularly in CD patients. Ongoing challenges, such as the risk of malnutrition, medication malabsorption, and postoperative IBD exacerbations, necessitate careful long-term follow-up.